Xbiom™ and iOmics™ integration arcs across nonclinical, clinical and genomic biomarkers for targeted therapeutic drug development and stratified patient selection
Foster City, CA, April 20, 2015 /PRNewswire/ — PointCross Life Sciences today announced a strategic partnership with InterpretOmics Pvt. Ltd. to provide an integrated Big Data and globally accessible environment for genomic interpretation and analysis of all biomarkers collected in the context of clinical trials and nonclinical studies. This platform will serve the needs of precise or multi-targeted drug candidates, stratified patient selection and ex post analysis of efficacy and disease progression free survival.
Highlighting the timing of this partnership, PointCross Life Sciences said, “The tidal shift to biology and genomics driven drug development and the need for precise, targeted clinical trials for reducing costs and improving efficacy for targeted patients has already happened. The integration of our Xbiom™ platform with iOmics allows us to address critical industry needs with a visionary integration capable of exploiting diverse data types to identify important safety and efficacy signals.”
Dr. Asoke Talukder, CSO of InterpretOmics, said, “Having developed tools for interpreting genomic data in patients for research and medical care, this partnership with PointCross will allow us to deliver benefits of genomic interpretation and precision medicine to clinical trials, and reduce the costs, risks and time of drug development.”
InterpretOmics provides the Life Sciences industry with next generation sequencing and a genome interpretation platform to derive insights for Biomarker and Drug target development. InterpretOmics recently received the 2015 Bio-Excellence Award for their innovations in biomedicine.